Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
Targeting ALK Rearrangements in NSCLC: Current State of the Art Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
ALK+ NSCLC Treatment Guidelines Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
FDA Approves Alectinib for ALK-Positive Lung Cancer Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
Neladalkib Shows Durable Responses in Heavily Pretreated ALK . . . Key Takeaways Neladalkib shows a 31% ORR in advanced ALK-positive NSCLC, with durable responses in 64% and 53% at 12 and 18 months, respectively The drug effectively penetrates the blood-brain barrier, showing significant intracranial activity, especially in lorlatinib-naïve patients and those with the ALK G1202R mutation
ALK Alterations and Treatment Options for ALK+ NSCLC Panelists review the discovery of ALK gene fusions and how they have reshaped the treatment landscape for a distinct subset of lung cancer patients They describe how these rearrangements activate
Real-world treatment sequencing and effectiveness of second . . . With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
Real-World Treatment and Outcomes in ALK-Rearranged NSCLC . . . ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the real-world setting We aim to describe initial and subsequent treatments used, survival outcomes, prognostic